Positive evaluations in multiple cancer types
Angle's (L:AGLE) proprietary cell separation system, Parsortix, can be used to capture and harvest circulating tumour cells from blood, enabling a liquid biopsy. In the near term, Parsortix is being evaluated for use in the presurgery triaging of ovarian masses, with a clinical study expected to commence in Q415. H215 has seen positive evaluations of Parsortix in lung, prostate and breast cancer, supporting its potential utility in the multi-billion dollar cancer care market. We value Angle at £96m.
100% sensitivity in lung cancer study
Cancer Research UK (CRUK) has published findings from its work in lung cancer comparing Parsortix to CellSearch, the FDA-approved antibody-based isolation system. The study found 100% sensitivity for Parsortix for small cell lung cancer at a ≥20 CTC threshold, compared to 83% for CellSearch at a ≥1 CTC threshold (and only 58% at a ≥5 CTC threshold). This demonstrates that Parsortix is able to harvest CTCs of a non-epithelial phenotype, which may otherwise be missed by antibody-based systems such as CellSearch.
To Read the Entire Report Please Click on the pdf File Below